Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M6,183Revenue $M312Net Margin (%)7.5Altman Z-Score5.5
Enterprise Value $M5,834EPS $0.2Operating Margin %7.7Piotroski F-Score6
P/E(ttm)282Beneish M-Score-2.9Pre-tax Margin (%)3.0Higher ROA y-yY
Price/Book20.510-y EBITDA Growth Rate %--Quick Ratio8.3Cash flow > EarningsY
Price/Sales20.15-y EBITDA Growth Rate %7.4Current Ratio8.4Lower Leverage y-yN
Price/Free Cash Flow76.9y-y EBITDA Growth Rate %--ROA % (ttm)2.6Higher Current Ratio y-yY
Dividend Yield %--PEG41.0ROE % (ttm)7.5Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M120ROIC % (ttm)--Gross Margin Increase y-yN

Gurus Latest Trades with ISIS

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
ISISJoel Greenblatt 2015-06-30 Add$56.05 - $68
($63.58)
$ 51.54-19%Add 88.03%14,839
ISISJoel Greenblatt 2015-03-31 Reduce$58.83 - $77.08
($67.85)
$ 51.54-24%Reduce 9.75%7,892
ISISJoel Greenblatt 2014-12-31 Buy $36.46 - $65.09
($49.54)
$ 51.544%New holding8,745
ISISRon Baron 2014-06-30 Sold Out -0.01%$22.98 - $43.33
($31.44)
$ 51.5464%Sold Out0
ISISGeorge Soros 2014-06-30 Sold Out $22.98 - $43.33
($31.44)
$ 51.5464%Sold Out0
ISISRon Baron 2014-03-31 Buy 0.01%$38.56 - $59
($48.28)
$ 51.547%New holding45,251
ISISGeorge Soros 2014-03-31 Buy $38.56 - $59
($48.28)
$ 51.547%New holding5,539
ISISGeorge Soros 2011-06-30 Sold Out $8.54 - $9.38
($8.92)
$ 51.54478%Sold Out0
ISISGeorge Soros 2011-03-31 Buy $8.57 - $10.35
($9.21)
$ 51.54460%New holding22,300
ISISFirst Eagle Investment 2010-12-31 Sold Out -0.01%$8.05 - $10.51
($9.48)
$ 51.54444%Sold Out0
ISISFirst Eagle Investment 2010-09-30 Buy 0.01%$7.775 - $10.07
($8.76)
$ 51.54488%New holding100,000
ISISGeorge Soros 2010-09-30 Sold Out $7.775 - $10.07
($8.76)
$ 51.54488%Sold Out0
ISISGeorge Soros 2010-06-30 Buy $8.84 - $11.13
($9.93)
$ 51.54419%New holding16,100
ISISFirst Eagle Investment 2010-03-31 Sold Out -0.01%$8.66 - $11.76
($10.31)
$ 51.54400%Sold Out0
ISISFirst Eagle Investment 2009-12-31 Buy 0.01%$9.94 - $14.16
($11.94)
$ 51.54332%New holding50,000
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

ISIS is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


ISIS: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
PARSHALL B LYNNECOO & Secretary 2015-07-06Sell6,218$57.01-9.59view
CROOKE STANLEY TChairman and CEO 2015-07-06Sell6,175$57.01-9.59view
Monia Brett PSVP, Antisense Drug Discovery 2015-07-02Sell198$56.3-8.45view
PARSHALL B LYNNECOO & Secretary 2015-07-01Sell6,218$57.56-10.46view
CROOKE STANLEY TChairman and CEO 2015-07-01Sell6,175$57.56-10.46view
Monia Brett PSVP, Antisense Drug Discovery 2015-06-08Sell7,600$66.22-22.17view
MUTO FREDERICK TDirector 2015-06-01Sell10,000$66.91-22.97view
PARSHALL B LYNNECOO & Secretary 2015-04-07Sell5,565$63.07-18.28view
CROOKE STANLEY TChairman and CEO 2015-04-07Sell22,377$63.07-18.28view
PARSHALL B LYNNECOO & Secretary 2015-04-01Sell5,377$61.93-16.78view

Quarterly/Annual Reports about ISIS:

News about ISIS:

Articles On GuruFocus.com
buffet May 31 2015 
buffet May 31 2015 
Bayer Enters Into Collaboration With Isis For Enhancing Its Drug Portfolio May 07 2015 
Analysts Provide Update for Biogen, PTC Therapeutics, GW Pharma, and Isis Pharma Apr 22 2015 
Value vs. Growth: Is Jim Cramer Right about ISIS Pharmaceuticals? Dec 13 2014 
Weekly CEO Sells Highlight: Keynote Systems Inc., Isis Pharmaceuticals, Coleman Cable Inc. Jul 01 2013 
Isis Pharmaceuticals Inc. (ISIS) Director, COO B Lynne Parshall sells 17,200 Shares Dec 29 2010 
Isis Pharmaceuticals Inc. (ISIS) Chairman, President, CEO Stanley T Crooke sells 32,000 Shares Dec 29 2010 
Isis Pharmaceuticals Inc. Reports Operating Results (10-Q) Nov 05 2010 
Isis Pharmaceuticals Inc. Reports Operating Results (10-Q) May 07 2010 

More From Other Websites
AstraZeneca and Isis Pharmaceuticals to discover and develop antisense drugs for cardiovascular,... Aug 20 2015
Regeneron Leads and Shire Dragged the Large-Cap Stocks Aug 19 2015
Zeltia SA Earnings Q2*, 2015 Aug 13 2015
5 Top BioPharma Stocks That May Have Sold Off Too Much and Become Bargains Aug 12 2015
ISIS PHARMACEUTICALS INC Financials Aug 11 2015
10-Q for Isis Pharmaceuticals, Inc. Aug 08 2015
ISIS PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report Aug 05 2015
Edited Transcript of ISIS earnings conference call or presentation 4-Aug-15 3:30pm GMT Aug 04 2015
Isis Pharmaceuticals (ISIS) Misses Earnings Estimates in Q2 - Tale of the Tape Aug 04 2015
Isis Reports Financial Results And Highlights For Second Quarter 2015 Aug 04 2015
Isis beats 2Q profit forecasts Aug 04 2015
Isis beats 2Q profit forecasts Aug 04 2015
ISIS PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition,... Aug 04 2015
Isis Reports Financial Results And Highlights For Second Quarter 2015 Aug 04 2015
Q2 2015 Isis Pharmaceuticals Inc Earnings Release - Before Market Open Aug 04 2015
Isis Reports Positive Data from KYNAMRO® (mipomersen sodium) FOCUS FH Phase 3 Study in Patients... Aug 03 2015
Isis Reports Positive Data from KYNAMRO® (mipomersen sodium) FOCUS FH Phase 3 Study in Patients... Aug 03 2015
Will Isis Pharmaceuticals (ISIS) Beat Q2 Earnings Estimates? - Analyst Blog Aug 03 2015
Isis Pharma 8-K Filing Shows Company Enters Agreement with Astrazeneca To Discover And Develop... Aug 03 2015

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.

User Comments

No comment yet
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK